Risks of Tacrolimus and Paxlovid Therapy in SARS-CoV-2 Positive Transplant Recipients: A Case Discussion and Institutional Data Review

他克莫司 医学 2019年冠状病毒病(COVID-19) 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 重症监护医学 2019-20冠状病毒爆发 病毒学 免疫学 移植 内科学 传染病(医学专业) 疾病 爆发
作者
Michael D. Olp,Ellen E. Higginson,Carmen Gherasim
出处
期刊:American Journal of Clinical Pathology [Oxford University Press]
卷期号:162 (Supplement_1): S17-S18
标识
DOI:10.1093/ajcp/aqae129.038
摘要

Abstract Introduction/Objective Transplant recipients maintained on immunosuppressants like tacrolimus continue to be at high risk for morbidity due to SARS-CoV-2 infection and are strong candidates for antiviral therapies. However, co- administration of the antiviral Paxlovid (nirmatrelvir/ritonavir) poses a significant risk to these patients due to ritonavir- mediated inhibition of CYP3A, an important mediator of tacrolimus metabolism. Consequently, Paxlovid therapy in post-organ transplant patients on tacrolimus requires careful consideration. Our investigation aims to assess the continuing risk posed by this drug-drug interaction and better understand clinical circumstances linked to critically high tacrolimus levels due to Paxlovid co-administration. Methods/Case Report We conducted a large-scale retrospective analysis of tacrolimus measurements at the University of Michigan Medicine beginning in January 2020. We also performed a detailed review of patients with critically high tacrolimus levels coinciding with Paxlovid administration. Results (if a Case Study enter NA) Of 39,752 tacrolimus measurements examined, 682 correspond to 329 patients with recent positive SARS-CoV-2 nucleic acid testing, and 37 correspond to 18 patients with documented Paxlovid co- administration. Patients receiving concurrent Paxlovid and tacrolimus demonstrate 1.6- and 1.8-fold higher mean tacrolimus levels (14.1 ng/mL, p = 3e-5) compared to other SARS-CoV-2 positive (8.7 ng/mL) and negative/untested (7.9 ng/mL) patients, respectively. Among SARS-CoV-2 patients, those prescribed Paxlovid are more likely to present with supratherapeutic tacrolimus levels (OR 4.1, 95% CI 1.6 – 10.7). A detailed case review of three organ transplant recipients presenting with tacrolimus levels >60 ng/mL and creatinine levels increased by 0.45 ± 0.27 mg/dL from baseline shows Paxlovid was prescribed at outside facilities, and regular tacrolimus dose was continued. Three other patients exhibited supratherapeutic tacrolimus levels (20 – 30 ng/mL), and creatinine levels increased by 0.41 ± 0.23 mg/dL from baseline despite dose reduction or cessation before initiating Paxlovid. Conclusion Our findings highlight the importance of communication between primary and tertiary care providers and caution when prescribing Paxlovid in populations managed with tacrolimus therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
刚刚
Nole的应助被今天没有哭鸭采纳,获得10
刚刚
Maestro_S的应助被shaco采纳,获得10
刚刚
lili完成签到,获得积分10
刚刚
脑洞疼的应助被15331970326采纳,获得10
1秒前
无极微光的应助被zhoudongxue采纳,获得20
1秒前
2秒前
朱晖发布了新的文献求助20
2秒前
今夜略闲发布了新的文献求助10
2秒前
2秒前
喔喔佳佳L发布了新的文献求助20
2秒前
入司的应助被李麟采纳,获得10
2秒前
Akim的应助被刘泽楷采纳,获得10
3秒前
英姑的应助被楠楠采纳,获得10
3秒前
3秒前
orixero的应助被annona采纳,获得30
3秒前
3秒前
4秒前
瘦瘦大米发布了新的文献求助10
4秒前
月亮完成签到,获得积分10
4秒前
Lucas的应助被Kyra采纳,获得10
4秒前
5秒前
搜集达人的应助被DW采纳,获得30
5秒前
6秒前
何文鑫发布了新的文献求助10
7秒前
刘锰发布了新的文献求助10
8秒前
8秒前
9秒前
迷路芝麻完成签到,获得积分10
9秒前
顾矜的应助被Blue灬boy采纳,获得10
10秒前
爆米花的应助被nana采纳,获得10
10秒前
10秒前
syvshc的应助被Elsevier大王采纳,获得10
11秒前
在水一方的应助被Elsevier大王采纳,获得10
11秒前
在水一方的应助被Elsevier大王采纳,获得10
11秒前
顺顺利利的应助被Elsevier大王采纳,获得10
11秒前
田様的应助被Elsevier大王采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188210
求助须知:如何正确求助?哪些是违规求助? 9576001
关于积分的说明 21844898
捐赠科研通 7786081
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482139